Literature DB >> 12973820

Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce.

Lucy Lee1, Joanne Kepple, Yibin Wang, Stephen Freestone, Ray Bakhtiar, Yanfeng Wang, Mohammad Hossain.   

Abstract

Ritalin, an immediate release form of racemic methylphenidate hydrochloride, has been available in the USA since 1955 and is used for the treatment of ADHD. The objective of this study was to evaluate the pharmacokinetics of modified-release methylphenidate (highest single dose), Ritalin LA, when administered under fasting condition, with a high-fat breakfast, and when sprinkled on applesauce in healthy adult subjects. Blood samples were drawn for 24 h following a 40 mg oral administration. Most subjects appeared to produce a bimodal methylphenidate plasma concentration profile. In all three treatment groups, methylphenidate was rapidly absorbed with an initial average t(max(0-4)) of 1.3-2.4 h and an average peak plasma concentration [C(max(abs))] of 14.4-15.2 ng/ml. On average, both the rate [C(max(abs)) and t(max(abs))] and the extent of absorption (AUC(0- infinity)) of methylphenidate were similar when the capsule was given with a high fat breakfast and when the capsule contents were sprinkled onto applesauce, compared with the fasting state. No dose dumping was observed when the capsule was given with a high fat breakfast or when sprinkled onto applesauce. The dose was safe and generally well tolerated. Coadministration of a single oral dose of 40 mg methylphenidate capsule whether administered intact with a high-fat breakfast or sprinkled on applesauce did not affect the overall rate or extent of absorption of methylphenidate compared with the fasted condition. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973820     DOI: 10.1002/bdd.358

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  10 in total

Review 1.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

2.  Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.

Authors:  Liang Li; Yaning Wang; Ramana S Uppoor; Mehul U Mehta; Tiffany Farchione; Mitchell V Mathis; Hao Zhu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-18       Impact factor: 2.745

Review 3.  Review and comparison of the long acting methylphenidate preparations.

Authors:  Feng Liu; Rafael Muniz; Haruka Minami; Raul R Silva
Journal:  Psychiatr Q       Date:  2005

4.  Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography.

Authors:  Kennerly S Patrick; Wendy Rodriguez
Journal:  Drug Metab Dispos       Date:  2019-04-26       Impact factor: 3.922

5.  Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Authors:  John S Markowitz; Arthur B Straughn; Kennerly S Patrick; C Lindsay DeVane; Linda Pestreich; James Lee; Yanfeng Wang; Rafael Muniz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Methylphenidate reduces functional connectivity of nucleus accumbens in brain reward circuit.

Authors:  J G Ramaekers; E A Evers; E L Theunissen; K P C Kuypers; A Goulas; P Stiers
Journal:  Psychopharmacology (Berl)       Date:  2013-04-19       Impact factor: 4.530

7.  Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

Authors:  Diane E May; Christopher J Kratochvil
Journal:  Drugs       Date:  2010       Impact factor: 9.546

8.  Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin ® LA) in school children under daily practice conditions.

Authors:  Fabian Haertling; Beate Mueller; Oliver Bilke-Hentsch
Journal:  Atten Defic Hyperact Disord       Date:  2014-10-28

9.  Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults.

Authors:  Xiaoxia Yang; John Duan; Jeffrey Fisher
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

10.  Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.

Authors:  Sharon B Wigal; Ann Childress; Sally A Berry; Heidi Belden; Faith Walters; Phillip Chappell; Nancy Sherman; John Orazem; Donna Palumbo
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-05-30       Impact factor: 2.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.